Members

Dr. Ambasta is a general internist with a research focus on healthcare quality and patient safety. Having completed a medical degree and post-graduate training in general internal medicine at the University of Calgary, Dr. Ambasta pursued a Masters in Public Health at the Harvard T.H. Chan School of Public Health with a focus on Clinical Effectiveness. She is an Assistant Professor in the Department of Anesthesiology, Pharmacology and Therapeutics at the University of British Columbia. Her overall research program focuses on reduction of low-value services in health systems. She is a member of the Choosing Wisely Canada national expert group dedicated to reducing unnecessary laboratory testing. Her research work in low-value laboratory testing has been funded by Alberta Health Services, Choosing Wisely Alberta, Canadian Society of Internal Medicine, Alberta Health Services, and Canadian Institutes of Health Research. Her ongoing research projects include implementation of a multi-modal intervention bundle to reduce low-value laboratory testing across hospitals in Alberta and British Columbia, collaboration with a patient and family advisory council to engage patients with reduction of low-value use of health care resources and describing linkages between low value use of diagnostic testing and therapeutic use in healthcare systems.

Wade is a pharmacist and researcher working to ensure older persons are taking medications that are necessary, effective, safe, and consistent with their healthcare goals and treatment preferences. This primarily involves developing and evaluating strategies to stop medications when they are no longer a good fit (“deprescribing”). Wade approaches deprescribing and polypharmacy management research with a multi-methods approach, incorporating qualitative methods, pharmacoepidemiological methods, knowledge translation, and implementation science. He is also an investigator with the deprescribing.org initiative. Wade has worked clinically as a pharmacist in long-term care, geriatric outpatient clinics, and primary care clinics.

Greg Carney completed his doctorate in Pharmacology and Therapeutics, with a focus on pharmacoepidemiology at the University of British Columbia. His PhD thesis examined the comparative safety and effectiveness of medications commonly used to aid smoking cessation. Greg has worked for the Therapeutics Initiative since 2003, and is currently Co-Chair of the PharmacoEpidemiology Group (PEG). Greg has 20 years of experience in analysing health care databases to evaluate pharmaceutical policy and program changes, and in conducting drug safety and effectiveness studies. His current research focus is on the implementation and evaluation of physician audit and feedback programs using randomized designed delay trials.

Dr. Aaron M Tejani, is a researcher/educator with the Therapeutics Initiative (co-chair of the Education Working Group, member of the Drug Assessment Working Group), clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), and Medication use evaluation pharmacist with Lower Mainland Pharmacy Services (Vancouver, BC). He completed his BSc(Pharm) at UBC (Vancouver) and Doctor of Pharmacy degree at Creighton University (Omaha, Nebraska).

Aaron is particularly interested in teaching healthcare professionals how to critically appraise evidence for medical interventions and how to use evidence in clinical practice/policy development. He is an author of a number of Therapeutics Letters.

Dr. Jessica Otte is a family physician in Nanaimo, BC. She has always been passionate about helping patients find the right health care according to the evidence and their needs and values, and she practices this daily with a focus on care of the elderly and palliative care. Dr Otte is deeply engaged in sharing this approach through continuing medical education, policy and medical leadership work, an active social media presence (@LessIsMoreMed), and teaching family practice residents.

Together with clinical expertise and patient values, Dr. Otte champions the values of the Therapeutics Initiative – rigorous and unbiased review of evidence –  in her quality improvement, policy, clinical guideline, and health technology assessment (HTA) contributions at the provincial and national levels.

Ciprian Jauca studied linguistics at the Babes-Bolyai University in Cluj-Napoca, Romania (major in Romance Languages, minor in Germanistic Studies) from 1986 to 1990. In 1991 he earned an International Diploma of Business Management and Intercultural Communication from the University of Osnabruck, Germany. He speaks several languages and has worked as translator and simultaneous interpreter, as well as managing social development projects for non-profit organizations. Ciprian joined the Therapeutics Initiative at its inception in 1994. He is the Managing Editor for the Therapeutics Letter and has been the Program Coordinator for the Therapeutics Initiative from its inception in 1994 until 2018. He created the Therapeutics Initiative website in the late 1990s and has been serving as its webmaster. He has been involved in the international Cochrane Collaboration since 2001, serving as the Managing Editor for Cochrane Hypertension. He has been involved in the International Society of Drug Bulletins since 2003, was elected as a member of the Executive Committee in 2008 and was elected Secretary General of the organization in 2016. Ciprian served as an elected member of the Board of Directors for the Association of Administrative and Professional Staff (AAPS) at the University of British Columbia from 2011 to 2015. Ciprian is currently serving as a member of the Board of Directors of the Laurier Institution, Treasurer and Chief Financial Officer of Colibri Learning Foundation and Vice-Chairman of the National Spiritual Assembly of the Bahá’í Community of Canada.

Balraj (Benji) Heran received a B.Sc. (Hon.) in Physiology at the UBC and joined the TI in 2000. He recently graduated from the Ph.D. program in the Department of Anesthesiology, Pharmacology and Therapeutics, UBC. Under the supervision of Dr. Jim Wright, he conducted two systematic reviews of the dose-related blood pressure lowering efficacy of ACE inhibitors and angiotensin receptor blockers for primary hypertension. Benji is also a contributing author of a number of systematic reviews and protocols published in the Cochrane Library. From 2003 to 2009 he has served on the editorial team of the Cochrane Collaboration Hypertension Review Group as the Trial Search Co-ordinator, since 2009 has been an Editor with the Cochrane Hypertension Group and a Postdoctoral Research Fellow with the Cochrane Heart Group. He has a keen interest in cardiovascular research.

Annabel recently completed a post-doctoral position at the University of Brighton, UK. This research mandate was based within the Shared Values workstream of the UKRI GCRF Action Against Stunting Hub focussing on informing local solutions through making explicit lived experiences and evaluating intangible project legacies. Her PhD was based within the same project and focussed on a qualitative values-based approach to localization of Global Health Projects. Annabel’s BSc and MSc were in Food Science and Human Nutrition. She has also worked within the charity sector in the UK in community engagement for the purpose of improving health and social care services in Hertfordshire. Annabel’s research priorities are participatory methods, knowledge exchange and implementation science.

Dr. Nima Alaeiilkhchi joined the TI in March 2024 as a postdoctoral fellow following the completion of his PhD in Neuroscience. His doctoral research was dedicated to exploring metabolic treatments for multiple sclerosis (MS) using murine models. This work reflects his passion for deepening his understanding of complex biological systems and his ambition to bridge the gap between laboratory research and clinical application as a future clinician-scientist. Moreover, with nearly a decade of experience working with the Cochrane Hypertension Group, Nima has developed a robust expertise in conducting systematic reviews.

Nima will collaborate with Dr. Wade Thompson and Dr. Anshula Ambasta, focusing on systematic reviews and evidence synthesis in the realm of deprescribing and the management of polypharmacy, particularly among older populations. His work under Dr. Thompson’s guidance involves employing a multi-methods approach to research, aiming to optimize medication use in alignment with patients’ healthcare goals and preferences. Concurrently, with Dr. Ambasta, he will contribute to qualitative research efforts targeted at enhancing healthcare quality and patient safety, with a keen interest in the reduction of low-value services. This collaborative work not only aligns with his passion for translating research into actionable clinical practices but also marks a significant step in his journey toward impactful translational research and clinician-scientist excellence.

Maggie is a graduate student supervised by Dr. Anshula Ambasta and Dr. Wade Thompson. She has completed her BSc at the University of Toronto, specialist in pharmacology and biomedical toxicology and minor in computer sciences. In her undergraduate research project, she has investigated the association between anhedonia and oxylipin concentrations in type 2 diabetes and prediabetes patients of the Sunnybrook Type 2 Diabetes Study.

Dr. Grenet completed his MD specializing in endocrinology and his PhD in clinical pharmacology at the University of Lyon 1. He is a hospital doctor at the pharmaco-toxicology department of the University Hospital of Lyon, and a member of the Evaluation and Modeling with the Therapeutic Effects Group at the Laboratory of Biometry and Evolutionary Biology, CNRS UMR 5558 Lyon 1. His research focuses on treatment evaluation, especially of drugs used in diabetes, metabolic diseases and cardiovascular risk factors, mostly using meta-analytical approaches.

As a one-year Visiting Scientist, Dr. Grenet has joined the Therapeutics Initiative team to collaborate notably with the Drug Assessment Working Group and the Cochrane Hypertension Group. He will pursue the INDANA project of individual participants data meta-analysis in high blood pressure, initiated by Prof. Francois Gueyffier. In the context of the growing overweight and obesity pandemic, he will assess the impact of the body mass index on the cardiovascular benefits of antihypertensive drugs. The results are expected to help personalizing evidence-based treatment of people affected by overweight or obesity and high blood pressure.

Gloria graduated with a Bachelor of Science (Honours Science) and Doctor of Pharmacy from the University of Waterloo in 2016. She is a community pharmacist working to incorporate deprescribing in a dispensary setting to try and minimize medication harm and burden. Gloria also enjoys getting to work with the Drug Assessment Working Group to learn critical appraisal skills, risk of bias assessments and work on systematic reviews.

Dr. Carole Lunny is a Senior Research Scientist, HEOR division of Precision AQ and affiliated with the Cochrane Hypertension Group, Therapeutics Initiative at the University of British Columbia. Dr Lunny completed her PhD training as a clinical epidemiologist and methodologist at Cochrane Australia in January 2019 from Monash University’s School of Public Health and Preventive Medicine. Dr Lunny specialises in methods for research synthesis and critical appraisal of systematic reviews, network meta-analyses, randomised controlled trials, overviews of reviews, and observational studies. She routinely tells people she is an expert in identifying bias and error in clinical research studies. Dr Lunny’s current academic research is focused on further testing of the the RoB NMA tool, methods for ‘overviews of reviews’, and an AI tool to automate the methodological quality and risk of bias at the systematic review-level called “WISEST AI”. You can access her publication at: https://pubmed.ncbi.nlm.nih.gov/?term=lunny+c&sort=date

Scott Garrison has degrees in engineering physics and medicine, as well as a PhD in experimental medicine from the University of British Columbia. He has worked in Richmond, BC as a full-time office and hospital-based family physician since 1992 and has been a member of GPAC working groups producing the current BC provincial guidelines for the management of hypertension, stroke and cardiovascular risk reduction. He sat on the Primary Care Advisory Council for the Vancouver Coastal Health Authority and was the President of the Medical Staff for Richmond Hospital. He is also a clinical assistant professor with the UBC Dept of Family Practice and the principle investigator of a clinical trial exploring the role of magnesium in muscle cramping.

Carolyn’s research interests are organized around providing health care decision makers with research based as well as contextualized research. An active producer of health technology assessment (HTA) from 1992, she builds on a foundation of research synthesis methodologies, incorporating critical appraisal, meta-analysis, utilization analysis and decision analysis using data from administrative databases, systematic reviews and clinical trials.

Doctoral and postdoctoral training has added health informatics and qualitative research perspectives and approaches to her investigations into how knowledge is used in socio-technical systems. Carolyn has a BHSc(PT) from McMaster, a MSc from the Department of Health Care and Epidemiology at UBC, a PhD in Health Informatics from the University of Victoria, and has completed a CIHR sponsored postdoctoral fellowship in Knowledge Translation at the University of Alberta.

I am a GP in Victoria BC with a special interest in lifestyle – specifically exercise as medicine – and the application of rational testing and prescribing. I graduated from McGill medicine in 2012, and obtained a diploma in lifestyle medicine from the American College of Lifestyle Medicine in 2019.  In my free time I coach and compete at a Masters level in weightlifting, practice yoga and mindfulness, and love being out in nature!

Barbara Mintzes is an Associate Professor at the School of Pharmacy and Charles Perkins Centre, University of Sydney. She has a PhD in epidemiology from the University of British Columbia (UBC; 2003) and was at the School of Population and Public Health at UBC before moving to Sydney in 2015. Her research is on pharmaceutical policy, including systematic reviews, observational research on regulatory policies, and drug utilization/ pharmacoepidemiology. She has studied the effects of direct-to-consumer advertising of medicines in the U.S. and Canada, and of the quality of information provided by sales representatives to family doctors in Canada, the U.S. and France. Barbara Mintzes and Colin Dormuth are jointly leading a research project that compares regulatory safety advisories on medicines over a 10-year period in Australia, Canada, the U.S. and Europe. Barbara has also worked for many years with consumer and women’s health organizations in Canada and internationally and is a member of the European network of Health Action International (HAI-Europe).

Elise is a graduate student supervised by Dr. Siyana Kurteva and Dr. Anshula Ambasta. She earned her Bachelor’s degree in Pharmacology from McGill University’s Department of Pharmacology and Therapeutics. Elise has gained research experience from her work at the Rosalind and Morris Goodman Cancer Institute, where she completed an undergraduate research project investigating the effect of an epigenetic modifying drug on triple-negative breast cancer metabolism. Additionally, Elise spent time in the Integrative Oncology Department of BC Cancer, where she contributed to a project investigating lung adenocarcinoma.

Michael Nesrallah is a theoretical physicist specializing in nonlinear and quantum optics. He has experience as a physics instructor and briefly worked for a quantum computing start-up. Prior to joining the Therapeutics Initiative, Michael worked at UBC’s Advanced Research Computing department as a consultant and researcher. Although his background is in physics and research computing, he has always been drawn to health sciences and helping others. Michael sees working at the TI as an opportunity to apply sound mathematical principles to health data and to contribute to evidence-based therapeutics research.

Peter is a health-services researcher at the Therapeutics Initiative with interests in physician education, knowledge translation and the generation of knowledge syntheses. He completed his undergraduate studies in Health Sciences, specializing in Global Health, and a Master of Science degree in Health Research Methodology at McMaster University, where his thesis focused on surgical learning curves of minimally invasive procedures. Peter is passionate about informing evidence-based practice and access to healthcare and medicines through rigorous study designs. At the Therapeutics Initiative, Peter is working on a Cochrane systematic review and meta-analysis evaluating the impact of post-market risk communications to healthcare providers on patient outcomes and prescribing patterns. He also assists with the production of educational modules for the management, evaluation, and analysis of Canadian administrative health data through the Canadian Network for Drug Effectiveness Studies.

Rita McCracken is a full-service family doctor and researcher living as an uninvited visitor on the unceded, traditional territories of the Coast Salish peoples, including the Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh), the xʷməθkwəy̓əm (Musqueam), and the Skwxwú7mesh (Squamish) Nations. She is a Assistant Professor in the Department of Family Practice at UBC and studies the availability of primary care in BC and reliable ways to measure changes in that availability. Her other research work includes assessing the effects of too much medication and effective methods to deprescribe those excessive medicines. She chose medicine as a second career after 10 years working in Human Resources, finished med school at the University of Calgary in 2006 and her doctoral studies at UBC in 2018.

Dana is a Research Manager at the Therapeutics Initiative. She holds a Master of Educational Technology (MET) from the University of BC and a BA (Honours) in Psychology from Trent University. She first joined the group in 2008, working with Dr. Malcolm Maclure on the Education for Quality Improvement in Patient Care (EQIP) project. She is now the coordinator of the CNODES Training Team and the manager of the Therapeutic Initiative’s Portrait program. She is interested in developing educational resources that build capacity for drug safety and effectiveness research and evidence-based health care.

Andrew Li is a graduate student under the guidance of Dr. Colin Dormuth. His research mainly focuses on using administrative healthcare databases to conduct studies related to drug safety and effectiveness. Previously, he studied psychology at the UBC where his research and education was generously supported by a SSHRC Canada Graduate Scholarship. Later, he worked as a Senior Economist with the BC Ministry of Health focusing on the evaluation and monitoring of alternative payment models for family physicians. During his down time, Andrew enjoys a variety of hobbies, such as running marathons, watching the Lakers, and working out.

Marco Perez obtained his MD degree at the University of Guadalajara, Mexico, in 1991. He completed his specialty in Intensive Care Medicine in 1996. He worked as practicing specialist in an intensive care unit for several years. He obtained his PhD in Pharmacology & Therapeutics at the University of British Columbia in 2010, specializing in hypertension and hypertensive emergencies. During his PhD, he conducted two Cochrane systematic reviews and a randomized controlled trial. He has also been a contributing author of a number of systematic reviews published in the Cochrane Library and other peer-reviewed medical journals. Since 2006 he has served on the editorial team of Cochrane Hypertension. He has also been actively involved with the Therapeutics Initiative in the drug assessment-working group, since 2003; and as a clinical reviewer with the Common Drug Review, since 2007. He has completed a postdoctoral research fellowship at the Institut de la Sante et Recherche Medicale (INSERM) in the Université de Lyon, France, working in an international (French/Canadian) hypertension research project.

Juliana Vanessa Rincón López is a medical doctor with a Master’s degree in Clinical Epidemiology. She has extensive experience in clinical data analysis and public health research. Her passion for evidence-based healthcare has led her to explore various topics, including patient safety outcomes and health system efficiency. Juliana has contributed to studies on the cost and quality of care, particularly in intensive care units and healthcare systems in Colombia. Currently, she is involved in projects that aim to integrate clinical decision-making with the best available evidence. She is also dedicated to teaching and mentoring young professionals, with a commitment to improving healthcare systems through rigorous research. In her spare time, Juliana enjoys watching movies of all genres, playing chess, traveling, and spending time with her family and her dog.

Originally from Montreal, Patrick studied pharmacology and obtained both his undergraduate and graduate degrees from McGill University. He took on several business development and management roles in the corporate world before dedicating his career to non-profit health research for advancement of medical sciences and the greater good. Prior to joining the Therapeutics Initiative, he was managing the extensive research portfolio of the cancer centre at Purdue University ranging from fundamental research to clinical trials. As the TI general manager, Patrick oversees daily operations, safeguards financial health, and provides strategic support to the working groups. What he appreciates the most working with the TI is its non-biased policy, openness to the world, and relentless pursuit of clinical evidence for drug therapy.

Ellen is a Research Project Manager at the Therapeutics Initiative. Originally from the East Coast, she has a BA in French Literature from Dalhousie University and a Diploma in Professional Writing and Editing from UVic. She received her Master’s in Public Administration from the University of Victoria in 2015. The focus of her master’s research was physicians’ experiences and attitudes toward interactions with pharmaceutical sales representatives. She began working as a research coordinator at UBC in 2008, and previously worked extensively with women’s health organizations, including the Canadian Women’s Health Network and DES (diethylstilbestrol) Action Canada. She is currently the Project Manager for a grant looking at the impact of international safety advisories on prescribing, and also works on various TI and CNODES projects.

Douglas M Salzwedel obtained a Master of Library and Information Science from the University of Western Ontario in 2001 and has worked as the Information Specialist for the Therapeutics Initiative and Cochrane Hypertension since June 2009.  In addition to information retrieval projects, he leads Cochrane Hypertension’s priority setting activities, and is a member of the Drug Assessment Working Group and the Communications and Outreach Group.

During his time with the TI, Douglas served on the Cochrane Information Specialists’ Executive from 2011 to 2017 and from 2015 to 2018 he provided induction training, software training, mentoring and ongoing support to Cochrane Information Specialists across Cochrane’s international network as a member of Cochrane’s Information Specialists’ Support Team.  He re-joined the Cochrane Information Specialists’ Executive in 2023 and is also a Co-Convenor of PRESSforum, a search peer review portal for health sciences librarians engaged in systematic review searching

Prior to joining the Therapeutics Initiative, Douglas was the information specialist for the Cochrane Effective Practice and Organisation of Care (EPOC) Review Group and a librarian at the University of Ottawa’s Institute of Population Health.

Raha has over 10 years of experience as a hospital pharmacist and a research assistant at the Pharmaceutical Care Department of Masih Daneshvari Hospital (Tehran, Iran), a university-affiliated medical and research institution, and a tertiary referral center for pulmonary diseases and lung transplantation.

She completed her Doctor of Pharmacy degree at the School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran, Iran in 2011. She is currently a graduate student in Pharmacology & Therapeutics at the University of British Columbia, Vancouver, Canada.

She is working under the joint supervision of Dr. Anshula Ambasta and Dr. Wade Thompson. Raha’s research work focuses on rationale drug use and deprescribing, particularly in cardiovascular medicine.

Raha is passionate about evidence-based medicine to ensure patient safety and optimal therapeutic outcomes. To date, she has 19 publications, which have been cited 426 times as of Jan, 2024 (https://scholar.google.com/citations?user=hT-T9PMAAAAJ&hl=en).

Mrinmayi graduated from the University of Victoria with a BA in Economics. As a part of the Economics Honours Program, she conducted original research under the guidance of economics professors and authored a thesis paper on studying the effects of pay transparency and pay equity laws on the gender pay gap in Canada. After graduating, she worked as an Analyst at Statistics Canada focusing on economic research and data analysis related to science, technology, and innovation in Canadian industries.

Michelle has extensive experience working with diverse methodologies using various types of databases, including administrative linked data, survey-based cohort data, and clinical trial data. Her previous research primarily focused on marginalized populations, such as people using drugs and individuals living with HIV. Her doctoral research focused on unregulated drug use and the effectiveness of its treatment. She applies machine learning techniques to uncover underlying drug use patterns and to understand their relationship with drug treatment engagement within a causal inference framework. Michelle holds a PhD in Public Health and an MSc in Statistics from the University of British Columbia.

Fiona is a community pharmacist and health services researcher passionate about improving access to and promoting safe use of prescription medications. She obtained her PhD in Epidemiology from McGill University, following her pharmacy degree and a master’s in Population and Public Health from the University of British Columbia. Her doctoral research focused on how physician-related factors influence the use of potentially inappropriate medications and how, after using these medications, the patient’s health outcomes varied depending on the physician they saw. With pharmacists’ scope of practice being expanded rapidly across Canada, her postdoctoral work (under the supervision of Dr. Colin Dormuth) aims to evaluate the impact of these changes on patients’ health, as well as on the health system at large.

Her work draws on methods from epidemiology, pharmacoepidemiology, health services research, and policy evaluation. She has substantial experience analyzing large, population-based administrative datasets from across Canada and the United States. She has also worked as a community pharmacist, specializing in care of older adults in assisted living and residential care settings.

Tom graduated from McGill University Medical School in 1978.  After a rotating internship at Dalhousie University and internal medicine residency in Vancouver, he achieved Fellowship in the Royal College of Physicians of Canada.  He took additional training at the Karolinska Institute Department of Clinical Pharmacology in Stockholm 1986-87 and at UBC until 1989, when he was elected to the Legislative Assembly of British Columbia.  Tom served as Opposition Health Critic from 1989-1991, then as Minister for Advanced Education, Training & Technology from 1991-93, and as a government MLA from 1993-96.  These experiences alerted him to the importance of getting good value for money in health care, in order to maintain an effective universal health service in Canada.
After returning to clinical medicine in 1996, Tom practiced general internal medicine with sick patients at Delta Hospital, UBC Hospital and Vancouver General Hospital until 2014.  Until the end of 2021, he maintained an outpatient internal medicine practice focused on pharmacological treatment of chronic pain and reducing polypharmacy (deprescribing).  He continues to teach clinical pharmacology through seminars, lectures, special courses, and webinars presented throughout British Columbia. Tom has a special interest in the use of videography to teach students and health professionals about drugs and about human pathophysiology.

Tom co-chairs the Education Working Group and is Editor in Chief of the Therapeutics Letter. His other interests include wilderness canoeing and hiking, environmental conservation, peace and social justice issues, music, reading, and his wife (an experienced RN) and two children (geologist and NP). He likes continuous thinking and learning about medicine and drug therapy, and especially enjoys our interactions with smart and dedicated health care colleagues (students, MDs, pharmacists, NPs, nurses, PAs, and others) throughout B.C. and around the world.  As of early 2022 he’s helping vaccinate British Columbians against Covid19 and hoping that the benefits of good medical science are extended rapidly to everyone on Earth.

Colin Dormuth has extensive experience using administrative health care databases to evaluate pharmaceutical policy changes and physician prescribing behaviour. He has been a member of the Therapeutics Initiative since 1995. His research focuses on drug safety and effectiveness, as well as the design and evaluation of reimbursement policies for prescription drugs. He has training in economic theory, applied econometrics, epidemiology, health services outcome research and biostatistics. Dr. Dormuth holds a Sc.D. and S.M. in epidemiology from Harvard University, an M.A. in economics from the University of Victoria, and a B.A. in economics from the University of Manitoba.

Ken Bassett conducts systematic reviews of the efficacy and safety of new and established drugs, as well as pharmaco-epidemiologic studies of serious adverse events associated with prescription drug therapy in British Columbia. His ongoing research interests are in the systematic review of drug therapy and drug funding policy.

James (Jim) Wright obtained his MD from the University of Alberta in 1968, his FRCP(C) in Internal Medicine in 1975 and his PhD in Pharmacology from McGill University in 1976. He worked as a specialist in Internal Medicine and Clinical Pharmacology from 1997-2021. He served as the Co-Managing Director of the Therapeutics Initiative and Editor-in-Chief of the Therapeutics Letter from 1994-2020. He currently sits on the Editorial Boards of PLoSOne and the Cochrane Library.
Dr. Wright’s research focuses on issues related to appropriate use of prescription drugs (particularly antihypertensive and lipid lowering drugs), Clinical Pharmacology, clinical trials, systematic review, meta-analysis and knowledge translation.